Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse

Cutan Ocul Toxicol. 2011 Dec;30(4):320-2. doi: 10.3109/15569527.2011.573834. Epub 2011 Apr 26.

Abstract

We report the clinical course of a 56-year-old patient diagnosed with toxic keratopathy due to topical anesthetic abuse. One month later, while a large corneal epithelial defect persisted, the cornea developed circumferential neovascularization that was treated with subconjunctival bevacizumab. Corneal neovascularization (CN) showed a dramatic regression 1 week after subconjunctival injection of bevacizumab. The epithelial defect slowly healed, no complications were observed, and no recurrence observed after 4 months of follow-up. In conclusion, bevacizumab may be valid complementary treatment in patients with CN secondary to topical anesthetic abuse. To our knowledge, this is the first case of CN due to topical anesthetic abuse benefiting from treatment of subconjunctival bevacizumab.

Publication types

  • Case Reports

MeSH terms

  • Anesthetics, Local / administration & dosage
  • Anesthetics, Local / adverse effects*
  • Anesthetics, Local / therapeutic use
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Corneal Neovascularization / chemically induced*
  • Corneal Neovascularization / drug therapy
  • Humans
  • Injections, Intraocular
  • Keratitis / drug therapy
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Tetracaine / administration & dosage
  • Tetracaine / adverse effects*
  • Tetracaine / therapeutic use
  • Treatment Outcome

Substances

  • Anesthetics, Local
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ophthalmic Solutions
  • Tetracaine
  • Bevacizumab